Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors
- PMID: 34878650
- DOI: 10.1111/bjd.20944
Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors
Abstract
We believe that there is significant interest in the role of IL-1 in the pathomechanism of palmoplantar pustulosis. However, the APRICOT study failed to demonstrate a therapeutic effect of the IL-1 receptor antagonist. So, we recommend that the authors perform an additional subgroup analysis based on the presence or absence of plaque psoriasis.
© 2022 British Association of Dermatologists.
Comment on
-
Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).Br J Dermatol. 2021 Aug 19;186(2):245-56. doi: 10.1111/bjd.20653. Online ahead of print. Br J Dermatol. 2021. PMID: 34411292 Free PMC article.
-
Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.Br J Dermatol. 2022 May;186(5):908. doi: 10.1111/bjd.20942. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34878653 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical